𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

✍ Scribed by Marianne Abifadel; Jean-Pierre Rabès; Martine Devillers; Arnold Munnich; Danièle Erlich; Claudine Junien; Mathilde Varret; Catherine Boileau

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
239 KB
Volume
30
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis

Hypercholesterolemia is one of the major causes of coronary heart disease (CHD). The genes encoding the low-density lipoprotein receptor and its ligand apolipoprotein B, have been the two genes classically implicated in autosomal dominant hypercholesterolemia (ADH). Our discovery in 2003 of the first mutations of the proprotein convertase subtilisin kexin 9 gene (PCSK9) causing ADH shed light on an unknown actor in cholesterol metabolism that since then has been extensively investigated. Several PCSK9 variants have been identified, some of them are gain-of-function mutations causing hypercholesterolemia by a reduction of low-density lipoprotein (LDL) receptor levels; while others are loss-of-function variants associated with a reduction of LDL-cholesterol (LDL-C) levels and a decreased risk of CHD. In this review, we focus on reported variants, and their biological, clinical, and functional relevance. We also highlight the spectrum of hypercholesterolemia or hypobetalipoproteinemia phenotypes that are already associated with mutations in PCSK9. Finally, we present future prospects concerning this therapeutic target that might constitute a new approach to reduce cholesterol levels and CHD, and enhance the effectiveness of other lipid-lowering drugs.

📜 SIMILAR VOLUMES

Proprotein convertase subtilisin/kexin t
Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells
✍ Hong Lan; Ling Pang; Marsha M. Smith; Diane Levitan; Wei Ding; Li Liu; Lixin Sha 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

## Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) induces degradation of low‐density lipoprotein receptor (LDLR) in the liver. It is being pursued as a therapeutic target for LDL‐cholesterol reduction. Earlier genome‐wide gene expression studies showed that PCSK9 over‐expression in

The molecular basis of familial hypercho
The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene
✍ Marianne Abifadel; Jean-Pierre Rabès; Sélim Jambart; Georges Halaby; Marie-Hélèn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

Autosomal dominant hypercholesterolemia (ADH), a major risk for coronary heart disease, is associated with mutations in the genes encoding the low-density lipoproteins receptor (LDLR), its ligand apolipoprotein B (APOB) or PCSK9 (Proprotein Convertase Subtilin Kexin 9). Familial hypercholesterolemia

A double mutant [N543H+2393del9] allele
A double mutant [N543H+2393del9] allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease
✍ S. Castillo; G. Reyes; D. Tejedor; P. Mozas; Y. Suarez; M.A. Lasuncion; A. Cenar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

Familial hypercholesterolemia is a genetic disorder caused by mutations in the LDL receptor gene. During a survey of mutations of LDL receptor gene in Spanish FH patients we found two mutations in the same allele: a missense N543H mutation in exon 11 and a 9bp inframe deletion (2393del9) located in